CCL2 and prostate carcinoma: It is observed that there is a strong association between CCL2 and MDR1. Activation of STAT3 upregulates the expression level of MDR1 and induces the emergence of paclitaxel and cabazitaxel resistance in prostate cancer cells [102, 103].